Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (108)	6/16/1998 11:59:00 PM
From: mike head	Read Replies (1) \| Respond to of 626

Hi, TD. Damn, now the site gets even more civil <g>. In my earlier posts, I stated a couple of times that I had the recolection of any mention of idiotypic stuff being negative. It hit me today. this was the subject matter of that much maligned paper in Cell by Immanichi-kari and David baltimore! Went back and read how after 10 years, the two where exonerated. Politics-bah, humbug! While searching around (hell of a lot of stuff on Jernes ideas and the not too succesful aplications therof), came across the following... Leave it to our scientists to clarify... David C. Young, M.D., Ph.D., Assistant Professor. LSU School of Medicine, 1988; Tulane University, 1983. The Fetal Autoimmune Repertoire and its Relationship to the Disease-associated Immune Response The objective of my research is to determine characteristics of disease-associated autoantibodies that identify autoimmune B cell clones that are suppressible by administered anti-idiotypic antibody. The hypothesis to be tested is that disease- associated autoantibodies that are similar to natural autoantibodies of the fetus will be subject to control by anti-idiotypic antibodies as occurs in the fetus. We are using the ELISA technique to examine self and anti-idiotypic reactivity of antibodies from the normal fetus and from patients. Binding and variable region sequence characteristics of these antibodies will be used to identify disease associated antibodies with fetal characteristics indicating the likelihood of susceptibility to regulation by anti-idiotypic antibody. Susceptibility of disease-associated B cells to regulation will be evaluated in vitro and in animal models. A tutorial in my laboratory will provide experience in cell culture, ELISA methodology, PCR, DNA cloning, and sequencing. Pax et bonum,mch